Buckley Wealth Management LLC raised its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 2.3% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 166,495 shares of the biopharmaceutical company’s stock after acquiring an additional 3,770 shares during the period. Pfizer comprises about 2.1% of Buckley Wealth Management LLC’s portfolio, making the stock its 13th largest holding. Buckley Wealth Management LLC’s holdings in Pfizer were worth $6,107,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Front Street Capital Management Inc. lifted its holdings in shares of Pfizer by 4.3% in the 1st quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after buying an additional 215 shares during the period. Synergy Asset Management LLC increased its holdings in shares of Pfizer by 3.3% in the 4th quarter. Synergy Asset Management LLC now owns 7,287 shares of the biopharmaceutical company’s stock valued at $373,000 after purchasing an additional 236 shares in the last quarter. Motco lifted its stake in shares of Pfizer by 0.8% in the fourth quarter. Motco now owns 31,376 shares of the biopharmaceutical company’s stock valued at $1,608,000 after purchasing an additional 236 shares during the period. OLD Point Trust & Financial Services N A grew its position in Pfizer by 0.5% during the fourth quarter. OLD Point Trust & Financial Services N A now owns 49,152 shares of the biopharmaceutical company’s stock worth $2,519,000 after buying an additional 250 shares during the period. Finally, Confluence Wealth Services Inc. increased its holdings in Pfizer by 0.5% in the fourth quarter. Confluence Wealth Services Inc. now owns 55,282 shares of the biopharmaceutical company’s stock valued at $2,833,000 after buying an additional 252 shares in the last quarter. Hedge funds and other institutional investors own 68.05% of the company’s stock.
Pfizer Stock Down 1.3 %
Shares of NYSE:PFE opened at $33.64 on Tuesday. The firm has a market cap of $189.93 billion, a PE ratio of 8.95, a price-to-earnings-growth ratio of 1.14 and a beta of 0.59. The company has a fifty day simple moving average of $35.80 and a 200 day simple moving average of $37.96. The company has a current ratio of 2.12, a quick ratio of 1.82 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a 12-month low of $33.44 and a 12-month high of $54.93.
Pfizer Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 5th. Shareholders of record on Friday, July 28th were issued a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a yield of 4.88%. The ex-dividend date of this dividend was Thursday, July 27th. Pfizer’s dividend payout ratio is presently 43.62%.
Analyst Ratings Changes
PFE has been the subject of several research analyst reports. Morgan Stanley dropped their price objective on Pfizer from $42.00 to $40.00 and set an “equal weight” rating for the company in a research note on Wednesday, August 2nd. JPMorgan Chase & Co. cut their price objective on Pfizer from $45.00 to $41.00 and set a “neutral” rating for the company in a research report on Monday, July 17th. StockNews.com began coverage on Pfizer in a research report on Thursday, August 17th. They issued a “hold” rating on the stock. Jefferies Financial Group decreased their price target on shares of Pfizer from $40.00 to $38.00 in a research note on Wednesday, August 2nd. Finally, Barclays reduced their price target on Pfizer from $40.00 to $38.00 in a research note on Tuesday, July 11th. Twelve equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $46.35.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
- Five stocks we like better than Pfizer
- How to Buy Gold Stock and Invest in Gold
- Hostess Acquisition, 3.3% Dividend Make J.M. Smucker a Sweet Deal
- How Can Investors Benefit From After-Hours Trading
- Nikola’s Stock Could Double in Price Within Weeks
- Insider Trades May Not Tell You What You Think
- Drones Can Lift AeroVironment Shares To New Heights
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.